top of page
Search


Aspen Neuroscience IPO Bets on Parkinson's Brain Cells Made From Skin
Aspen Neuroscience raised about $140.6 million in its Nasdaq IPO to take sasineprocel, a one time Parkinson's therapy made from each patient's own skin cells, toward a Phase 3 trial. Early data looks encouraging, the shares priced at the bottom of the range and manufacturing takes months per patient. Can medicine built one patient at a time become a public company business?
Oct 30


A Cancer Vaccine Built for One Patient Cuts Melanoma Relapse Risk by 42%
A cancer vaccine designed from one patient's own tumor DNA just passed its biggest test. In a Phase 3 trial of 1,137 people with high-risk melanoma, Moderna and Merck's intismeran plus Keytruda cut the risk of relapse or death by 42 percent, yet Moderna's stock still fell. Here is how a made-for-one vaccine is built, the debate over its value and the signals to watch. Will personalized cancer vaccines become routine care?
Oct 22


FDA Approves Hibsago, the First Functional Cure Option for Hepatitis B
The FDA has approved Hibsago, an antisense drug from GSK discovered by California's Ionis, that let about one in five eligible chronic hepatitis B patients keep the virus in check after stopping all treatment. Here is what was approved, how well it works, why hepatitis B hits the Bay Area's Asian American communities hard, and a bigger question: will hepatitis B become curable for most patients?
Oct 21


Can We Give Our Children a Genetic Head Start? Silicon Valley Thinks So.
A new class of startups will rank your IVF embryos by their odds of heart disease, Alzheimer's, height and even IQ, for up to $50,000 on top of the IVF itself. A Coinbase founder has given the ambition a name, the Gattaca stack, and the medical societies that govern genetics say the science is not ready. Is optimizing a baby the next Silicon Valley product category, or a line the Valley should not cross?
Oct 19


Could AI Give Doctors More Time to Care for Patients?
Digital healthcare promised efficiency, but doctors and nurses still spend hours trapped behind screens typing reports. A new localized medical AI called MedBobi is designed to solve this by quietly handling clinical documentation and shift handoffs—giving healthcare professionals back their most valuable asset: the time to focus on caring for patients.
Jul 16


The Startup Rethinking One of Orthopedics’ Most Difficult Repairs
Aztron Medtech is rethinking Achilles tendon repair with an ultrasound-guided, minimally invasive system designed to help surgeons perform precise repairs through tiny incisions. With its TendMIN® technology already entering U.S. operating rooms, the startup is showing how Taiwan’s strength in precision engineering can help shape the future of orthopedic surgery.
Jul 16


The Biotech Startup Trying to Change What Diabetes Treatment Can Do
Pharmasaga is developing a new approach to diabetes treatment by targeting the biological processes behind pancreatic beta-cell failure. With its lead drug candidate now in clinical development, the biotech startup is pursuing a future where diabetes may be treated at its source—not simply managed for life.
Jul 11


The Dementia Treatment That Might One Day Look Like a Nasal Spray
What if the future of dementia treatment did not look like surgery, injections, or hospital infusions — but a simple nasal spray? Researchers at Texas A&M have developed an experimental therapy that delivers microRNA-rich extracellular vesicles directly to the brain, reducing inflammation, restoring mitochondrial function, and improving memory in preclinical studies. While it is not yet a proven human treatment, the research points toward a powerful possibility: that brain ag
Jun 2


Why Longevity May Become Silicon Valley’s Most Human Moonshot
What if aging becomes less of an inevitability and more of an engineering challenge? As science, AI, biotech, and venture capital converge around longevity, the real goal is not simply to live longer — it is to extend the years when people remain healthy, independent, creative, and connected. This article explores why longevity may become Silicon Valley’s most human moonshot, and why the future of longer life will reshape family, healthcare, work, and society itself.
May 18


The End of Metal Implants? How Expercy Is Rewriting the Future of Healing
What if the best implant is the one that disappears? Expercy is challenging decades of orthopedic convention with absorbable biomaterials that don’t just support healing—they actively accelerate it, then dissolve when the job is done. From veterinary breakthroughs to future human applications, this is a new paradigm for surgery, recovery, and the role of medical devices in the body.
Apr 18


Diagnosis in 5 Minutes: The End of Traditional Radiology?
CephalonAI is compressing radiology diagnosis into minutes—while quietly reshaping the future of surgery, dementia care, and clinical decision-making.
Apr 18


The Invisible Molecule That Might Rewrite Medicine — Or Spark Its Next Debate
What if the most powerful new therapy in medicine wasn’t complex—but invisible? HOHO Biotech is betting on molecular hydrogen to reshape how we approach inflammation, aging, and chronic disease—challenging everything we thought we knew about treatment.
Apr 18


The End of Animal Testing? How Fluidiconic’s “Tumor-on-a-Chip” Is Rewriting the Future of Cancer Drug Discovery
What if the future of cancer drug discovery no longer depends on animal testing? Fluidiconic Biotechnology is building a new paradigm with its tumor-on-a-chip platform—recreating human tumor environments in vitro and accelerating how therapies are tested, validated, and brought to market. As pharma, biotech, and AI-driven drug discovery collide, this breakthrough could redefine the entire pipeline.
Apr 16


The End of Human-Limited Science? How Coherence Is Rewiring Drug Discovery at Machine Speed
What if the real bottleneck in drug discovery isn’t intelligence—but execution? Coherence is reimagining the laboratory itself as a programmable system, where AI doesn’t just predict outcomes but actively runs experiments, learns from results, and accelerates discovery at machine speed. As biology becomes increasingly digitized, Coherence offers a glimpse into a future where scientific breakthroughs are no longer limited by human throughput—and where the pace of innovation co
Apr 16


The Future of Healing Isn’t Synthetic — It’s Collagen Rewritten
What if healing didn’t rely on synthetic implants, but on materials the body already understands? FMG Biomed is pushing a new frontier with collagen-based biomaterials that guide the body to regenerate itself—reshaping wound care, bone repair, and the future of regenerative medicine.
Apr 16


The Invisible Revolution in Medicine: How Nanotechnology Is Quietly Rewriting the Rules of Diagnosis and Cancer Treatment
What if the future of medicine isn’t about stronger drugs—but smarter delivery? MegaPro by AP Biosciences is redefining how we diagnose and treat disease through nanotechnology, from Phase III MRI contrast agents to precision-targeted cancer therapies. This is where medicine becomes engineered.
Apr 15


The Algorithm That Decides Life: Can AI Finally Fix IVF’s 40% Problem?
IVF success has long been capped at around 40%, leaving patients with uncertainty and repeated cycles. AB DigiHealth is changing that equation by shifting embryo selection from visual assessment to AI-driven genomic analysis—unlocking deeper insights directly from NGS data. The result is a potential leap in implantation success and a new frontier for reproductive medicine.
Apr 15


The Sensor That Could Replace ICU Catheters: Are We Ready to Let a Capsule Monitor Our Organs From Within?
What if the future of critical care could be swallowed? DotSpace’s PressureDOT is redefining how we monitor life-threatening conditions—turning invasive procedures into seamless, continuous insights from within the body.
Apr 15


This New Tech Could Change How We Heal Ligaments Forever
What if ligament repair didn’t mean replacement—but regeneration? Developed by Industrial Technology Research Institute, LigamiX™ is a bioengineered ligament designed to help the body heal itself. With a porous, bionic structure and advanced biocomposite materials, it promotes tissue integration, reduces inflammation, and offers a new path forward for orthopedic recovery.
Mar 30


Ancient Romans Ate This Fish to Hallucinate — Scientists Are Now Studying Its Biology
An ordinary-looking fish in the Mediterranean hides a remarkable secret. Under certain conditions, eating the Sarpa salpa—also known as the dreamfish—can trigger vivid hallucinations lasting up to 36 hours. Ancient Romans reportedly served it at banquets for its mind-altering effects. Today, scientists are looking beyond the strange folklore and asking a deeper question: could the biology behind this fish reveal clues about how the human brain works—and even inspire new treat
Mar 5
bottom of page